drugset / Trial / NCT00485628

Safety Study in Outpatient Japanese Children With ADHD

NCT00485628

Phase 2 Completed 37 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and efficacy of atomoxetine in Japanese pediatric patients with ADHD.

Timeline

Start
2003-04
Primary completion
Completion
2003-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified